Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial (Clinical Rheumatology, (2018), 37, 5, (1417-1420), 10.1007/s10067-018-4074-6)

Patrick Durez; Karel Pavelka; Maria Alicia Lazaro; Abraham Garcia-Kutzbach; Robert J. Moots; Howard Amital; Marinella Govoni; Nathan Vastesaeger

doi:10.1007/s10067-018-4131-1

Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial (Clinical Rheumatology, (2018), 37, 5, (1417-1420), 10.1007/s10067-018-4074-6)

Patrick Durez^*, Karel Pavelka, Maria Alicia Lazaro, Abraham Garcia-Kutzbach, Robert J. Moots, Howard Amital, Marinella Govoni, Nathan Vastesaeger

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Abstract

The original publication contains two areas which require correcting. None of these errors change the results or conclusions of the article, but the authors wish to highlight the areas of change to the reader.

Original language	English
Pages (from-to)	2017-2018
Number of pages	2
Journal	Clinical Rheumatology
Volume	37
Issue number	7
DOIs	https://doi.org/10.1007/s10067-018-4131-1
State	Published - 1 Jul 2018
Externally published	Yes

Access to Document

10.1007/s10067-018-4131-1

Fingerprint

Dive into the research topics of 'Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial (Clinical Rheumatology, (2018), 37, 5, (1417-1420), 10.1007/s10067-018-4074-6)'. Together they form a unique fingerprint.

Cite this

Durez, P., Pavelka, K., Lazaro, M. A., Garcia-Kutzbach, A., Moots, R. J., Amital, H., Govoni, M., & Vastesaeger, N. (2018). Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial (Clinical Rheumatology, (2018), 37, 5, (1417-1420), 10.1007/s10067-018-4074-6). Clinical Rheumatology, 37(7), 2017-2018. https://doi.org/10.1007/s10067-018-4131-1

@article{5cca964b360c45769151f7f99b37690a,

title = "Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial (Clinical Rheumatology, (2018), 37, 5, (1417-1420), 10.1007/s10067-018-4074-6)",

abstract = "The original publication contains two areas which require correcting. None of these errors change the results or conclusions of the article, but the authors wish to highlight the areas of change to the reader.",

author = "Patrick Durez and Karel Pavelka and Lazaro, {Maria Alicia} and Abraham Garcia-Kutzbach and Moots, {Robert J.} and Howard Amital and Marinella Govoni and Nathan Vastesaeger",

note = "Publisher Copyright: {\textcopyright} 2018, International League of Associations for Rheumatology (ILAR).",

year = "2018",

month = jul,

day = "1",

doi = "10.1007/s10067-018-4131-1",

language = "אנגלית",

volume = "37",

pages = "2017--2018",

journal = "Clinical Rheumatology",

issn = "0770-3198",

publisher = "Springer London",

number = "7",

}

Durez, P, Pavelka, K, Lazaro, MA, Garcia-Kutzbach, A, Moots, RJ, Amital, H, Govoni, M & Vastesaeger, N 2018, 'Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial (Clinical Rheumatology, (2018), 37, 5, (1417-1420), 10.1007/s10067-018-4074-6)', Clinical Rheumatology, vol. 37, no. 7, pp. 2017-2018. https://doi.org/10.1007/s10067-018-4131-1

Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial (Clinical Rheumatology, (2018), 37, 5, (1417-1420), 10.1007/s10067-018-4074-6). / Durez, Patrick; Pavelka, Karel; Lazaro, Maria Alicia et al.
In: Clinical Rheumatology, Vol. 37, No. 7, 01.07.2018, p. 2017-2018.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial (Clinical Rheumatology, (2018), 37, 5, (1417-1420), 10.1007/s10067-018-4074-6)

AU - Durez, Patrick

AU - Pavelka, Karel

AU - Lazaro, Maria Alicia

AU - Garcia-Kutzbach, Abraham

AU - Moots, Robert J.

AU - Amital, Howard

AU - Govoni, Marinella

AU - Vastesaeger, Nathan

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The original publication contains two areas which require correcting. None of these errors change the results or conclusions of the article, but the authors wish to highlight the areas of change to the reader.

AB - The original publication contains two areas which require correcting. None of these errors change the results or conclusions of the article, but the authors wish to highlight the areas of change to the reader.

UR - http://www.scopus.com/inward/record.url?scp=85046752487&partnerID=8YFLogxK

U2 - 10.1007/s10067-018-4131-1

DO - 10.1007/s10067-018-4131-1

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 29752584

AN - SCOPUS:85046752487

SN - 0770-3198

VL - 37

SP - 2017

EP - 2018

JO - Clinical Rheumatology

JF - Clinical Rheumatology

IS - 7

ER -

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H et al. Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial (Clinical Rheumatology, (2018), 37, 5, (1417-1420), 10.1007/s10067-018-4074-6). Clinical Rheumatology. 2018 Jul 1;37(7):2017-2018. doi: 10.1007/s10067-018-4131-1

Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial (Clinical Rheumatology, (2018), 37, 5, (1417-1420), 10.1007/s10067-018-4074-6)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this